BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical ...

today announced the Company will exhibit four poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, which is being held from May 13-17, 2025 ...

today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in ...

Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025 Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...

today announced that the company will present a poster highlighting the preclinical activity of epetraborole against M. abscessus on Thursday, May 29, 2025 at the Nontuberculous Mycobacteria ...

"We are honored that our Trial in Progress poster has been accepted for presentation at ASCO 2025," said Anastasios Maniakas, MD, PhD, Assistant Professor in the Department of Head and Neck ...

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation ... presented in a poster entitled ...

today provided additional details on the Trials in Progress poster presentation at the upcoming 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, being held from May 30 ...